|
|
Post by letitride on Feb 2, 2022 22:07:10 GMT -5
I make no guesses. I just hope the pps drops way down ... so I can buy more shares before people realize that they are idiots !!! But, that's mytakeonit My theory of investing is buy what everyone wants before they know they want it. Their not idiots they just dont know what they want. |
|
|
|
Post by cretin11 on Feb 2, 2022 22:38:36 GMT -5
I make no guesses. I just hope the pps drops way down ... so I can buy more shares before people realize that they are idiots !!! But, that's mytakeonit My theory of investing is buy what everyone wants before they know they want it. Their not idiots they just dont know what they want. Some of us were many years ahead of “them” when it comes to MNKD. 😂 |
|
|
|
Post by mytakeonit on Feb 3, 2022 1:09:14 GMT -5
So cretin means buying at 80 cents  But, that's mytakeonit |
|
|
|
Post by falconquest on Feb 9, 2022 22:43:31 GMT -5
Hypothetically speaking if this happens and Technosphere takes off it's possible that the street would perceive Afrezza as the albatross around the companies neck. More like a White Elephant. Rare, precious, sacred, expensive to maintain. If the Street is not completely dominated by idiots, and I don’t think it is, then Afrezza is not an albatross, but it could still be very difficult for it to obtain marketshare. Mining precious metal is difficult and expensive but it’s not an albatross around the neck of the miners. Expensive to maintain and also expensive to market. Any efforts thus far have not proved fruitful. Making money on Tyvaso only to spend it on marketing Afrezza may seem a lost cause. However, this is only a guess on how "the street" may perceive Mannkind. It is not my opinion, just a guess. I'm certainly not writing off Afrezza at all. |
|
|
|
Post by prcgorman2 on Feb 10, 2022 1:11:23 GMT -5
More like a White Elephant. Rare, precious, sacred, expensive to maintain. If the Street is not completely dominated by idiots, and I don’t think it is, then Afrezza is not an albatross, but it could still be very difficult for it to obtain marketshare. Mining precious metal is difficult and expensive but it’s not an albatross around the neck of the miners. Expensive to maintain and also expensive to market. Any efforts thus far have not proved fruitful. Making money on Tyvaso only to spend it on marketing Afrezza may seem a lost cause. However, this is only a guess on how "the street" may perceive Mannkind. It is not my opinion, just a guess. I'm certainly not writing off Afrezza at all. Al Mann didn’t spend more than $1B of his own money on a whim. A market truism is, “follow the smart money”. Dr. Mann was very, very smart. And, Afrezza is an utra-rapid acting inhalable human insulin and does a much better job than any competitive RAA of mimicing a healthy pancreas when used correctly for mealtime needs. From a PK/PD perspective, Afrezza appears to be a slam dunk. “Life changing” has been said by users more than once. If Tyvaso pays for Afrezza to be successful, it will be spectacular. Lost cause? We won’t know until the clinical studies and insurance coverage hurdles have been overcome. If it is a lost cause, we shareholders may lose time, but don’t know that we’ll lose money. The goal is marketshare equity with Novolog and Humalog. It’s a real goal with real value for both shareholders and PWDs. If it can be achieved, we’ll see more than one zero following the integer leading the share price. Dr. Mann asserted that Afrezza would be, “the best selling drug of all time”. It’s possible he was right, and worth the effort to find out. |
|
|
|
Post by falconquest on Feb 16, 2022 21:32:09 GMT -5
Expensive to maintain and also expensive to market. Any efforts thus far have not proved fruitful. Making money on Tyvaso only to spend it on marketing Afrezza may seem a lost cause. However, this is only a guess on how "the street" may perceive Mannkind. It is not my opinion, just a guess. I'm certainly not writing off Afrezza at all. Al Mann didn’t spend more than $1B of his own money on a whim. A market truism is, “follow the smart money”. Dr. Mann was very, very smart. And, Afrezza is an utra-rapid acting inhalable human insulin and does a much better job than any competitive RAA of mimicing a healthy pancreas when used correctly for mealtime needs. From a PK/PD perspective, Afrezza appears to be a slam dunk. “Life changing” has been said by users more than once. If Tyvaso pays for Afrezza to be successful, it will be spectacular. Lost cause? We won’t know until the clinical studies and insurance coverage hurdles have been overcome. If it is a lost cause, we shareholders may lose time, but don’t know that we’ll lose money. The goal is marketshare equity with Novolog and Humalog. It’s a real goal with real value for both shareholders and PWDs. If it can be achieved, we’ll see more than one zero following the integer leading the share price. Dr. Mann asserted that Afrezza would be, “the best selling drug of all time”. It’s possible he was right, and worth the effort to find out. And I'm not doubting what you're saying at all however, none of that matters. It's how the market "perceives" Mannkind that matters. I think the success of Tyvaso will determine the future of Technosphere and therefore Mannkind. |
|
|
|
Post by prcgorman2 on Feb 17, 2022 7:28:56 GMT -5
Al Mann didn’t spend more than $1B of his own money on a whim. A market truism is, “follow the smart money”. Dr. Mann was very, very smart. And, Afrezza is an utra-rapid acting inhalable human insulin and does a much better job than any competitive RAA of mimicing a healthy pancreas when used correctly for mealtime needs. From a PK/PD perspective, Afrezza appears to be a slam dunk. “Life changing” has been said by users more than once. If Tyvaso pays for Afrezza to be successful, it will be spectacular. Lost cause? We won’t know until the clinical studies and insurance coverage hurdles have been overcome. If it is a lost cause, we shareholders may lose time, but don’t know that we’ll lose money. The goal is marketshare equity with Novolog and Humalog. It’s a real goal with real value for both shareholders and PWDs. If it can be achieved, we’ll see more than one zero following the integer leading the share price. Dr. Mann asserted that Afrezza would be, “the best selling drug of all time”. It’s possible he was right, and worth the effort to find out. And I'm not doubting what you're saying at all however, none of that matters. It's how the market "perceives" Mannkind that matters. I think the success of Tyvaso will determine the future of Technosphere and therefore Mannkind. You may be right about the impact Tyvaso will have on the future of Mannkind. Only time will tell. Respectfully though, the efforts of Mannkind, and the money spent by a self-made multibillionaire who achieved his wealth because of his genius treating diabetes with the minimed pump do, in fact, matter. If it weren’t for that, I can’t imagine any of the longtime longs who post here would own MNKD stock. I think faith in those expenditures and that effort and the current state with regard to the UTHR partnership on Tyvaso DPI are the reasons that institutional ownership increased so much over the last couple of years. They are as much “the market” that is perceiving Mannkind as anybody. |
|
|
|
Post by cretin11 on Feb 18, 2022 6:27:51 GMT -5
The money spent by a self-made millionaire got us to $55 per share. Tragically he is no longer around. MNKD management of Afrezza (and hence market perception) shredded that $55 per share valuation. It’s naive to think Al’s genius helps our market perception today, even though it’s a reason many of us got into this many years ago. What will change market perception going forward is revenue and profitability, and we are counting on Martine’s genius to get us there.
|
|
|
|
Post by prcgorman2 on Feb 18, 2022 7:13:16 GMT -5
The money spent by a self-made millionaire got us to $55 per share. Tragically he is no longer around. MNKD management of Afrezza (and hence market perception) shredded that $55 per share valuation. It’s naive to think Al’s genius helps our market perception today, even though it’s a reason many of us got into this many years ago. What will change market perception going forward is revenue and profitability, and we are counting on Martine’s genius to get us there. Afrezza is Al Mann’s genius. It didn’t end with Dr. Mann’s death. And neither did the challenges that have been largely overcome by the current management. You can predict what will change market perception, and it is safe to say revenue and profitability will do that, but that platitude isn’t all there is to it and we both know it. And, I agree it is fair to say Dr. Rothblatt’s genius is providing an assist, but if you’re going to give Martine credit, you also have to admit that she chose to do business with Mannkind and the current management, not despite it. |
|
|
|
Post by cretin11 on Feb 18, 2022 7:43:04 GMT -5
“but if you’re going to give Martine credit, you also have to admit that she chose to do business with Mannkind and the current management, not despite it.”
No, we don’t need to admit that at all. Quite possible that Martine chose to do business with MNKD because of the superior technology (again, that was Al’s brainchild and he actually was a genius) and despite MNKD’s current management.
|
|
|
|
Post by prcgorman2 on Feb 18, 2022 7:49:09 GMT -5
“but if you’re going to give Martine credit, you also have to admit that she chose to do business with Mannkind and the current management, not despite it.” No, we don’t need to admit that at all. Quite possible that Martine chose to do business with MNKD because of the superior technology (again, that was Al’s brainchild and he actually was a genius) and despite MNKD’s current management. Rubbish. It is not “quite possible”. It’s extremely unlikely. You don’t sign contracts with a drug, you sign them with people. If Martine thought they were fools, she would be a fool to contract with them. Let it go. |
|
|
|
Post by cretin11 on Feb 18, 2022 9:51:02 GMT -5
“but if you’re going to give Martine credit, you also have to admit that she chose to do business with Mannkind and the current management, not despite it.” No, we don’t need to admit that at all. Quite possible that Martine chose to do business with MNKD because of the superior technology (again, that was Al’s brainchild and he actually was a genius) and despite MNKD’s current management. Rubbish. It is not “quite possible”. It’s extremely unlikely. You don’t sign contracts with a drug, you sign them with people. If Martine thought they were fools, she would be a fool to contract with them. Let it go. Nobody said Martine thinks they are “fools” - again your habit of moving the goalposts to fit your narrative. TS is what Martine wants to utilize. So yes, it is possible that she chose to utilize TS despite current management of MNKD. She’s not choosing MNKD for its marketing or sales expertise, that’s for sure. Sorry it hurts your feelings, and it’s not the degree of enthusiasm you want to see. We know any questioning of management does not meet with your approval. TS is legit, Afrezza proved it despite management’s failure to commercialize it. Hopefully UTHR can use the TS platform to generate huge profits. Basically it’s what falconquest said, Tyvaso is key for the success of TS and our market perception. |
|
|
|
Post by peppy on Feb 18, 2022 9:59:35 GMT -5
cretin, do you live in your mother's basement? cretin11asking for a friend. |
|
|
|
Post by jkendra on Feb 18, 2022 10:05:26 GMT -5
Rubbish. It is not “quite possible”. It’s extremely unlikely. You don’t sign contracts with a drug, you sign them with people. If Martine thought they were fools, she would be a fool to contract with them. Let it go. Nobody said Martine thinks they are “fools” - again your habit of moving the goalposts to fit your narrative. TS is what Martine wants to utilize. So yes, it is possible that she chose to utilize TS despite current management of MNKD. She’s not choosing MNKD for its marketing or sales expertise, that’s for sure. Sorry it hurts your feelings, and it’s not the degree of enthusiasm you want to see. We know any questioning of management does not meet with your approval. TS is legit, Afrezza proved it despite management’s failure to commercialize it. Hopefully UTHR can use the TS platform to generate huge profits. That will move the needle and thus “market perception” will follow. What is so great about Technosphere® Technology ? |
|
|
|
Post by peppy on Feb 18, 2022 10:36:34 GMT -5
Nobody said Martine thinks they are “fools” - again your habit of moving the goalposts to fit your narrative. TS is what Martine wants to utilize. So yes, it is possible that she chose to utilize TS despite current management of MNKD. She’s not choosing MNKD for its marketing or sales expertise, that’s for sure. Sorry it hurts your feelings, and it’s not the degree of enthusiasm you want to see. We know any questioning of management does not meet with your approval. TS is legit, Afrezza proved it despite management’s failure to commercialize it. Hopefully UTHR can use the TS platform to generate huge profits. That will move the needle and thus “market perception” will follow. What is so great about Technosphere® Technology ? access to the blood stream through alveoli. An IV of sorts, with a quicker onset of action. More targeted. Capable of protein delivery, as in amino acids. enzymes and molecules made up of amino acids. I am providing a coloring book.   |
|
